Author
David Cameron
Other affiliations: Universidade Nova de Lisboa, Cameron International, University of Edinburgh ...read more
Bio: David Cameron is an academic researcher from University of Oslo. The author has contributed to research in topics: Large Hadron Collider & Breast cancer. The author has an hindex of 154, co-authored 1586 publications receiving 126067 citations. Previous affiliations of David Cameron include Universidade Nova de Lisboa & Cameron International.
Topics: Large Hadron Collider, Breast cancer, Higgs boson, Lepton, Top quark
Papers published on a yearly basis
Papers
More filters
••
TL;DR: In this paper, the authors presented the double-differential cross-section of the jet transverse momentum and the dimensionless quantity x(T) = 2p(T)/root s, in bins of jet rapidity.
Abstract: The inclusive jet cross-section has been measured in proton-proton collisions at root s = 2.76 TeV in a dataset corresponding to an integrated luminosity of 0.20 pb(-1) collected with the ATLAS detector at the Large Hadron Collider in 2011. Jets are identified using the anti-k(t) algorithm with two radius parameters of 0.4 and 0.6. The inclusive jet double-differential cross-section is presented as a function of the jet transverse momentum p(T) and jet rapidity y, covering a range of 20 <= p(T) < 430 GeV and vertical bar y vertical bar < 4.4. The ratio of the cross-section to the inclusive jet cross-section measurement at root s = 7 TeV, published by the ATLAS Collaboration, is calculated as a function of both transverse momentum and the dimensionless quantity x(T) = 2p(T)/root s, in bins of jet rapidity. The systematic uncertainties on the ratios are significantly reduced due to the cancellation of correlated uncertainties in the two measurements. Results are compared to the prediction from next-to-leading order perturbative QCD calculations corrected for non-perturbative effects, and next-to-leading order Monte Carlo simulation. Furthermore, the ATLAS jet cross-section measurements at root s = 2.76 TeV and root s = 7 TeV are analysed within a framework of next-to-leading order perturbative QCD calculations to determine parton distribution functions of the proton, taking into account the correlations between the measurements.
115 citations
••
TL;DR: The randomized EORTC phase II trial of E vs T, which showed promising activity in 1st line MBC was extended in a phase III reported here, aiming at a true comparison of efficacy and tolerability of both drugs.
Abstract: 515 Background: E is an aromatase inactivator, with demonstrated efficacy in MBC progressing under T, which remained standard 1st line HT over decades. The randomized EORTC phase II trial of E vs T, which showed promising activity in 1st line MBC (Ann. Oncol. 2003, 14: 1391–8) was extended in a phase III reported here, aiming at a true comparison of efficacy and tolerability of both drugs. Methods: Postmenopausal MBC pts with ECOG PS ≤2 and measurable, hormone responsive disease (ER &/or PgR + or unknown with disease free interval >2y) previously untreated with HT for MBC, were randomized to receive open label E 25mg or T 20mg daily. One prior chemotherapy (CT) for MBC was permitted. Prior adjuvant T was allowed if treatment free interval exceeded 6 mo. The trial was powered to detect an increase in median progression free survival (PFS, primary endpoint) of 3 mo in favor of E. Secondary endpoints were survival and tolerability. All analyses were intent to treat. Results: 382 pts accrued by 81 centers rec...
114 citations
••
University of Cambridge1, The Breast Cancer Research Foundation2, University of Warwick3, Cambridge University Hospitals NHS Foundation Trust4, Western General Hospital5, Peterborough City Hospital6, University of Nottingham7, West Middlesex University Hospital8, Royal Bournemouth Hospital9, Royal Surrey County Hospital10, Ontario Institute for Cancer Research11, Edinburgh Cancer Research Centre12
TL;DR: Addition of four cycles of bevacizumab to D-FEC in HER2-negative early breast cancer significantly improved pathological complete response, however, whether the improvement in pathologicalcomplete response will lead to improved disease-free and overall survival outcomes is unknown.
Abstract: Summary Background The ARTemis trial was developed to assess the efficacy and safety of adding bevacizumab to standard neoadjuvant chemotherapy in HER2-negative early breast cancer. Methods In this randomised, open-label, phase 3 trial, we enrolled women (≥18 years) with newly diagnosed HER2-negative early invasive breast cancer (radiological tumour size >20 mm, with or without axillary involvement), at 66 centres in the UK. Patients were randomly assigned via a central computerised minimisation procedure to three cycles of docetaxel (100 mg/m 2 once every 21 days) followed by three cycles of fluorouracil (500 mg/m 2 ), epirubicin (100 mg/m 2 ), and cyclophosphamide (500 mg/m 2 ) once every 21 days (D-FEC), without or with four cycles of bevacizumab (15 mg/kg) (Bev+D-FEC). The primary endpoint was pathological complete response, defined as the absence of invasive disease in the breast and axillary lymph nodes, analysed by intention to treat. The trial has completed and follow-up is ongoing. This trial is registered with EudraCT (2008-002322-11), ISRCTN (68502941), and ClinicalTrials.gov (NCT01093235). Findings Between May 7, 2009, and Jan 9, 2013, we randomly allocated 800 participants to D-FEC (n=401) and Bev+D-FEC (n=399). 781 patients were available for the primary endpoint analysis. Significantly more patients in the bevacizumab group achieved a pathological complete response compared with those treated with chemotherapy alone: 87 (22%, 95% CI 18–27) of 388 patients in the Bev+D-FEC group compared with 66 (17%, 13–21) of 393 patients in the D-FEC group (p=0·03). Grade 3 and 4 toxicities were reported at expected levels in both groups, although more patients had grade 4 neutropenia in the Bev+D-FEC group than in the D-FEC group (85 [22%] vs 68 [17%]). Interpretation Addition of four cycles of bevacizumab to D-FEC in HER2-negative early breast cancer significantly improved pathological complete response. However, whether the improvement in pathological complete response will lead to improved disease-free and overall survival outcomes is unknown and will be reported after longer follow-up. Meta-analysis of available neoadjuvant trials is likely to be the only way to define subgroups of early breast cancer that would have clinically significant long-term benefit from bevacizumab treatment. Funding Cancer Research UK, Roche, Sanofi-Aventis.
114 citations
••
Aix-Marseille University1, University of Oklahoma2, Academia Sinica3, University of Paris-Sud4, Azerbaijan National Academy of Sciences5, University of Amsterdam6, Oklahoma State University–Stillwater7, Michigan State University8, University of Toronto9, Tel Aviv University10, University of Bergen11, Yale University12, University of Oslo13, Technion – Israel Institute of Technology14, CERN15, AGH University of Science and Technology16, Brookhaven National Laboratory17, Ludwig Maximilian University of Munich18, Rutherford Appleton Laboratory19, University of Belgrade20, University of Liverpool21, University of Bern22, Boston University23, University of Rome Tor Vergata24, Stockholm University25
TL;DR: In this article, the first study of WWjj, same-electric-charge diboson production in association with two jets, using 20.3 fb−1 of proton-proton collision data at ffiffiffis p ¼ 8 TeV recorded b...
Abstract: This Letter presents the first study of WWjj, same-electric-charge diboson production in associationwith two jets, using 20.3 fb−1 of proton-proton collision data at ffiffiffis p ¼ 8 TeV recorded b ...
113 citations
••
Aix-Marseille University1, University of Oklahoma2, Academia Sinica3, University of Paris-Sud4, Azerbaijan National Academy of Sciences5, University of Amsterdam6, Oklahoma State University–Stillwater7, Michigan State University8, Tel Aviv University9, University of Bergen10, Brookhaven National Laboratory11, University of Oslo12, Yale University13, Technion – Israel Institute of Technology14, CERN15, AGH University of Science and Technology16, Ludwig Maximilian University of Munich17, Rutherford Appleton Laboratory18, University of Belgrade19, University of Liverpool20, Stockholm University21, Lund University22
TL;DR: In this article, the results of a search for lepton jets in proton-proton collisions at the centre-of-mass energy of root s = 8 TeV in a sample of 20.3 fb(-1) collected during 2012 with the ATLAS detector at the LHC were presented.
Abstract: Several models of physics beyond the Standard Model predict neutral particles that decay into final states consisting of collimated jets of light leptons and hadrons (so-called "lepton jets"). These particles can also be long-lived with decay length comparable to, or even larger than, the LHC detectors' linear dimensions. This paper presents the results of a search for lepton jets in proton-proton collisions at the centre-of-mass energy of root s = 8 TeV in a sample of 20.3 fb(-1) collected during 2012 with the ATLAS detector at the LHC. Limits on models predicting Higgs boson decays to neutral long-lived lepton jets are derived as a function of the particle's proper decay length.
112 citations
Cited by
More filters
••
TL;DR: The GLOBOCAN 2020 estimates of cancer incidence and mortality produced by the International Agency for Research on Cancer (IARC) as mentioned in this paper show that female breast cancer has surpassed lung cancer as the most commonly diagnosed cancer, with an estimated 2.3 million new cases (11.7%), followed by lung cancer, colorectal (11 4.4%), liver (8.3%), stomach (7.7%) and female breast (6.9%), and cervical cancer (5.6%) cancers.
Abstract: This article provides an update on the global cancer burden using the GLOBOCAN 2020 estimates of cancer incidence and mortality produced by the International Agency for Research on Cancer. Worldwide, an estimated 19.3 million new cancer cases (18.1 million excluding nonmelanoma skin cancer) and almost 10.0 million cancer deaths (9.9 million excluding nonmelanoma skin cancer) occurred in 2020. Female breast cancer has surpassed lung cancer as the most commonly diagnosed cancer, with an estimated 2.3 million new cases (11.7%), followed by lung (11.4%), colorectal (10.0 %), prostate (7.3%), and stomach (5.6%) cancers. Lung cancer remained the leading cause of cancer death, with an estimated 1.8 million deaths (18%), followed by colorectal (9.4%), liver (8.3%), stomach (7.7%), and female breast (6.9%) cancers. Overall incidence was from 2-fold to 3-fold higher in transitioned versus transitioning countries for both sexes, whereas mortality varied <2-fold for men and little for women. Death rates for female breast and cervical cancers, however, were considerably higher in transitioning versus transitioned countries (15.0 vs 12.8 per 100,000 and 12.4 vs 5.2 per 100,000, respectively). The global cancer burden is expected to be 28.4 million cases in 2040, a 47% rise from 2020, with a larger increase in transitioning (64% to 95%) versus transitioned (32% to 56%) countries due to demographic changes, although this may be further exacerbated by increasing risk factors associated with globalization and a growing economy. Efforts to build a sustainable infrastructure for the dissemination of cancer prevention measures and provision of cancer care in transitioning countries is critical for global cancer control.
35,190 citations
••
[...]
TL;DR: There is, I think, something ethereal about i —the square root of minus one, which seems an odd beast at that time—an intruder hovering on the edge of reality.
Abstract: There is, I think, something ethereal about i —the square root of minus one. I remember first hearing about it at school. It seemed an odd beast at that time—an intruder hovering on the edge of reality.
Usually familiarity dulls this sense of the bizarre, but in the case of i it was the reverse: over the years the sense of its surreal nature intensified. It seemed that it was impossible to write mathematics that described the real world in …
33,785 citations
•
28,685 citations
••
University of Colorado Boulder1, Harvard University2, Mayo Clinic3, Boston University4, University of Pennsylvania5, University of Pittsburgh6, University of Siena7, University Health Network8, Institut Gustave Roussy9, Oregon Health & Science University10, University of Texas MD Anderson Cancer Center11, Duke University12, University of Cincinnati13, Memorial Sloan Kettering Cancer Center14, MedStar Washington Hospital Center15
TL;DR: Evidence-based recommendations are developed to inform clinical decision-making in the management of thyroid nodules and differentiated thyroid cancer and represent, in the authors' opinion, contemporary optimal care for patients with these disorders.
Abstract: Background: Thyroid nodules are a common clinical problem, and differentiated thyroid cancer is becoming increasingly prevalent. Since the American Thyroid Association's (ATA's) guidelines for the management of these disorders were revised in 2009, significant scientific advances have occurred in the field. The aim of these guidelines is to inform clinicians, patients, researchers, and health policy makers on published evidence relating to the diagnosis and management of thyroid nodules and differentiated thyroid cancer. Methods: The specific clinical questions addressed in these guidelines were based on prior versions of the guidelines, stakeholder input, and input of task force members. Task force panel members were educated on knowledge synthesis methods, including electronic database searching, review and selection of relevant citations, and critical appraisal of selected studies. Published English language articles on adults were eligible for inclusion. The American College of Physicians Guideline Gr...
10,501 citations
••
[...]
TL;DR: In this paper, a sedimentological core and petrographic characterisation of samples from eleven boreholes from the Lower Carboniferous of Bowland Basin (Northwest England) is presented.
Abstract: Deposits of clastic carbonate-dominated (calciclastic) sedimentary slope systems in the rock record have been identified mostly as linearly-consistent carbonate apron deposits, even though most ancient clastic carbonate slope deposits fit the submarine fan systems better. Calciclastic submarine fans are consequently rarely described and are poorly understood. Subsequently, very little is known especially in mud-dominated calciclastic submarine fan systems. Presented in this study are a sedimentological core and petrographic characterisation of samples from eleven boreholes from the Lower Carboniferous of Bowland Basin (Northwest England) that reveals a >250 m thick calciturbidite complex deposited in a calciclastic submarine fan setting. Seven facies are recognised from core and thin section characterisation and are grouped into three carbonate turbidite sequences. They include: 1) Calciturbidites, comprising mostly of highto low-density, wavy-laminated bioclast-rich facies; 2) low-density densite mudstones which are characterised by planar laminated and unlaminated muddominated facies; and 3) Calcidebrites which are muddy or hyper-concentrated debrisflow deposits occurring as poorly-sorted, chaotic, mud-supported floatstones. These
9,929 citations